Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with OGX-427 vs placebo in advanced transitional cell carcinoma
2011-002424-41Phase 2Completed
- Sponsor
- Achieve Life Sciences
- Start
- Aug 2011
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apatorsen in transitional cell carcinoma (TCC) (3 arms), sponsored by Achieve Life Sciences. Primary endpoint: Overall survival. Started Aug 2011; status: completed.
02
Drugs
apatorsen
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2011-002424-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002424-41.